MedTrace Logo

Paromomycin for Individuals With Uncomplicated Cutaneous Leishmaniasis

NCT01641796 · Status: NO_LONGER_AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2020-05-15

No results posted yet for this study

Summary

This is an expanded access treatment protocol designed to provide a topical cream treatment option to military health care beneficiaries with parasitologically confirmed uncomplicated Cutaneous Leishmaniasis.

Conditions

  • Leishmaniasis, Cutaneous

Interventions

DRUG

Paromomycin

Paromomycin Topical Cream applied to all lesions once a day for 20 days

Sponsors & Collaborators

  • U.S. Army Medical Research and Development Command

    lead FED

Principal Investigators

  • Naomi Aronson, MD · Uniformed Services University of the Health Sciences

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01641796 on ClinicalTrials.gov